Did You Know...
...that on Dec. 15, 1836, the Patent Office was completely destroyed by fire? Lost were some 7,000 models, 9,000 drawings, and 230 books plus all records of patent applications and grants.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173695 | Kappa selective opioid receptor antagonist A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions. ... | 05/08/2012 |
| 8153683 | Methods of treatment using a prodrug of an excitatory amino acid This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psych... | 04/10/2012 |
| 8101638 | 6-substituted nicotinamide derivatives as opioid receptor antagonists A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as desc... | 01/24/2012 |
| 8093302 | Substituted tetralins as selective estrogen receptor-β agonists The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypert... | 01/10/2012 |
| 8088800 | 4-(5-aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity The present invention relates to compounds of formulae (I) and (II) useful as opioid receptor antagonists for the treatment of obesity, wherein p is 0, 1, or 2; y is 0, 1, or 2; and z is 0, 1, or 2; X1 is CH2, CH, or N; to form a indolinyl, ind... | 01/03/2012 |
| 8071776 | Thienopyridines as allosteric potentiators of the M4 muscarinic receptor The present invention relates to selective allosteric potentiators of the Formula (I): or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M4 muscarinic receptors. ... | 12/06/2011 |
| 8058425 | Purine derivatives as kinase inhibitors The present invention provides kinase inhibitors of Formula I. ... | 11/15/2011 |
| 8022065 | Purine derivatives as kinase inhibitors The present invention provides kinase inhibitors of Formula I. ... | 09/20/2011 |
| 7981892 | Disubstituted phthalazine hedgehog pathway antagonists The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer. ... | 07/19/2011 |
| 7964632 | Methods of treatment using a prodrug of an excitatory amino acid This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psych... | 06/21/2011 |
| 7943670 | Liquid formulations of ractopamine Described is a soluble stable liquid formulation, process for preparing, and a method of using the soluble stable liquid formulation comprising ractopamine or a physiologically acceptable salt thereof, a liquid nonionic cosolvent, and water. ... | 05/17/2011 |
| 7902372 | Opioid receptor antagonists A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mi... | 03/08/2011 |
| 7842822 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia. ... | 11/30/2010 |
| 7834187 | Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate, a pharmaceutical formulation containing... | 11/16/2010 |
| 7709522 | Kappa selective opioid receptor antagonist A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schi... | 05/04/2010 |
| 7709447 | Use of spinosyns for wound healing A spinosyn or a physiologically acceptable derivative or salt thereof for promoting or accelerating wound healing in humans. ... | 05/04/2010 |
| 7585985 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia. ... | 09/08/2009 |
| 7560463 | Diaryl ethers as opioid receptor antagonists Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome. ... | 07/14/2009 |
| 7531557 | Diaryl ethers as opioid receptor antagonists Compound 6-(2-fluoro-4-[[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl]-phenoxy)-nicotinamide, or a pharmaceutically acceptable salt thereof, is useful for the treatment of alcoholism. ... | 05/12/2009 |
| 7462647 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —Oâ€... | 12/09/2008 |
| 7442812 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor β agonists for treating Estrogen Receptor β mediated diseases such as benign prostatic hyperplasia. ... | 10/28/2008 |
| 7414132 | Opioid receptor antagonists A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3′, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereom... | 08/19/2008 |
| 7399774 | 6-substituted nicotinamide derivatives as opioid receptor antagonists A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as des... | 07/15/2008 |
| 7396943 | Opioid receptor antagonists A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed. | 07/08/2008 |
| 7381750 | Amino-phenoxymethyl-benzamide opioid receptor antagonists A compound of the formula (I) wherein the variables X1, X2, R1 to R7 including R3′, j, k, p, y, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful fo... | 06/03/2008 |
| 7381719 | Diaryl ethers as opioid receptor antagonist A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer o... | 06/03/2008 |
| 7378448 | Diphenylether amide derivatives as opioid receptor antagonists A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mi... | 05/27/2008 |
| 7375229 | Dihydro-dibenzo[B,E]oxepine based selective estrogen receptor modulators, compositions and methods The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C2-C6 | 05/20/2008 |
| 7354951 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to novel benzopyran ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hype... | 04/08/2008 |
| 7288543 | Opioid receptor antagonists A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3′, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the trea... | 10/30/2007 |
| 7279499 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such ago... | 10/09/2007 |
| 7271264 | Pentacyclic oxepines and derivatives thereof, compositions and methods The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C2-C6 | 09/18/2007 |
| 7265127 | βadrenergic agonists The present invention relates to 2-imidazo[1,2-a]pyridine group containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 09/04/2007 |
| 7253181 | βadrenergic agonists The present invention relates to pyrrolopyridine-3-yl group containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 08/07/2007 |
| 7241772 | βadrenergic agonists The present invention relates to 2-imidazo[1,5-a]pyridine containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 07/10/2007 |
| 7217734 | Substituted benzopyrans as selective estrogen receptor-beta agonists The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor β agonists. Such ag... | 05/15/2007 |
| 7214697 | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as βagonists The present invention relates to a β3 adrenergic receptor agonist of formula (I), wherein R is C3–C8 alkyl or (C3–C7 cycloalkyl)C1–C5 alk-di-yl: R1 is H, CN, halo; C1... | 05/08/2007 |
| 7208505 | β3 adrenergic agonists The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity... | 04/24/2007 |
| 7205407 | 3-Substituted oxindole β3 agonists The present invention relates to a β3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity ... | 04/17/2007 |
| 7196100 | Opioid receptor antagonists A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3′, E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer... | 03/27/2007 |
